Exploring snake venom-derived molecules for cancer treatment: challenges and opportunities

HTML Full Text

Reference

1. Utkin YN. Animal venom studies: Current benefits and future developments. World J Biol Chem. 2015;6(2):28. https://doi.org/10.4331/wjbc.v6.i2.28
2. Munawar A, Ali SA, Akrem A, Betzel C. Snake venom peptides: tools of biodiscovery. Toxins (Basel). 2018;10(11):474. https://doi.org/10.3390/toxins10110474
3. Undheim EAB, Georgieva DN, Thoen HH, Norman JA, Mork J, Betzel C, et al. Venom on ice: first insights into Antarctic octopus venoms. Toxicon. 2010 Nov;56(6):897-913. https://doi.org/10.1016/j.toxicon.2010.06.013
4. King GF. Venoms as a platform for human drugs: translating toxins into therapeutics. Expert Opin Biol Ther. 2011 Nov;11(11):1469- 84. https://doi.org/10.1517/14712598.2011.621940
5. Ruder T, Ali SA, Ormerod K, Brust A, Roymanchadi ML, Ventura S, et al. Functional characterization on invertebrate and vertebrate tissues of tachykinin peptides from octopus venoms. Peptides (NY). 2013;47:71-6. https://doi.org/10.1016/j.peptides.2013.07.002
6. Dutertre S, Jin AH, Vetter I, Hamilton B, Sunagar K, Lavergne V, et al. Evolution of separate predation- and defence-evoked venoms in carnivorous cone snails. Nat Commun. 2014;5:3521. https://doi.org/10.1038/ncomms4521
7. Koh CY, Kini RM. From snake venom toxins to therapeutics-- cardiovascular examples. Toxicon. 2012 ;59(4):497-506. https://doi.org/10.1016/j.toxicon.2011.03.017
8. Simoes-Silva R, Alfonso J, Gomez A, Holanda RJ, Sobrinho JC, Zaqueo KD, et al. Snake venom, a natural library of new potential therapeutic molecules: challenges and current perspectives. Curr Pharm Biotechnol. 2018 Jun 21;19(4):308-35. https://doi.org/10.2174/1389201019666180620111025
9. Otvos RA, Heus F, Vonk FJ, Halff J, Bruyneel B, Paliukhovich I, et al. Analytical workflow for rapid screening and purification of bioactives from venom proteomes. Toxicon. 2013 Dec 15;76:270-81. https://doi.org/10.1016/j.toxicon.2013.10.013
10. Liu S, Yang F, Zhang Q, Sun MZ, Gao Y, Shao S. "Anatomical" view of the protein composition and protein characteristics for gloydius shedaoensis snake venom via proteomics approach. Anat Record. 2011 ;294(2):273-82. https://doi.org/10.1002/ar.21322
11. Georgieva D, Arni RK, Betzel C. Proteome analysis of snake venom toxins: pharmacological insights. Expert Rev Proteomics. 2014 Dec;5(6):787-97. https://doi.org/10.1586/14789450.5.6.787
12. Ediss.sub.hamburg. Analysis of the low molecular weight peptides of selected snake venoms. [cited 2022 Jul 28]. Available from: https:// ediss.sub.uni-hamburg.de/handle/ediss/4696
13. Lewis RJ, Garcia ML. Therapeutic potential of venom peptides. Nat Rev Drug Discov 2003;2(10):790-802. https://doi.org/10.1038/nrd1197
14. Tu AT. Overview of snake venom chemistry. Adv Exp Med Biol. 1996;391:37-62. https://doi.org/10.1007/978-1-4613-0361-9_3
15. Oliveira AL, Viegas MF, da Silva SL, Soares AM, Ramos MJ, Fernandes PA. The chemistry of snake venom and its medicinal potential. Nat Rev Chem. 2022;6(7):451-69. https://doi.org/10.1038/s41570-022-00393-7
16. Gutiérrez JM, Lomonte B. Phospholipases A2: unveiling the secrets of a functionally versatile group of snake venom toxins. Toxicon. 2013 Feb 1;62:27-39. https://doi.org/10.1016/j.toxicon.2012.09.006
17. Kini RM, Koh CY. Snake venom three-finger toxins and their potential in drug development targeting cardiovascular diseases. Biochem Pharmacol. 2020 Nov 1;181:114105. https://doi.org/10.1016/j.bcp.2020.114105
18. Kang TS, Georgieva D, Genov N, Murakami MT, Sinha M, Kumar RP, et al. Enzymatic toxins from snake venom: structural characterization and mechanism of catalysis. FEBS J. 2011 Dec 1;278(23):4544-76. https://doi.org/10.1111/j.1742-4658.2011.08115.x
19. Ullah A, Masood R, Ali I, Ullah K, Ali H, Akbar H, et al. Thrombin-like enzymes from snake venom: Structural characterization and mechanism of action. Int J Biol Macromol. 2018 Jul 15;114:788- 811. https://doi.org/10.1016/j.ijbiomac.2018.03.164
20. Hiu JJ, Yap MKK. Cytotoxicity of snake venom enzymatic toxins: phospholipase A2 and l-amino acid oxidase. Biochem Soc Trans. 2020 Apr 29;48(2):719-31. https://doi.org/10.1042/BST20200110
21. Tan KK, Bay BH, Gopalakrishnakone P. L-amino acid oxidase from snake venom and its anticancer potential. Toxicon. 2018 Mar 15;144:7-13. https://doi.org/10.1016/j.toxicon.2018.01.015
22. Arlinghaus FT, Eble JA. C-type lectin-like proteins from snake venoms. Toxicon. 2012 Sep 15;60(4):512-9. https://doi.org/10.1016/j.toxicon.2012.03.001
23. Morita T. Structures and functions of snake venom CLPs (C-type lectin-like proteins) with anticoagulant-, procoagulant-, and platelet-modulating activities. Toxicon. 2005 Jun 15;45(8):1099-114. https://doi.org/10.1016/j.toxicon.2005.02.021
24. Lu Q, Navdaev A, Clemetson JM, Clemetson KJ. Snake venom C-type lectins interacting with platelet receptors. Structure-function relationships and effects on haemostasis. Toxicon. 2005 Jun 15;45(8):1089-98. https://doi.org/10.1016/j.toxicon.2005.02.022
25. Vink S, Jin AH, Poth KJ, Head GA, Alewood PF. Natriuretic peptide drug leads from snake venom. Toxicon. 2012 Mar 15;59(4):434-45. https://doi.org/10.1016/j.toxicon.2010.12.001
26. Sridharan S, Kini RM, Richards AM. Venom natriuretic peptides guide the design of heart failure therapeutics. Pharmacol Res. 2020 May 1;155:104687. https://doi.org/10.1016/j.phrs.2020.104687
27. Six DA, Dennis EA. The expanding superfamily of phospholipase A2 enzymes: classification and characterization. Biochim Biophys Acta (BBA). 2000 Oct 31;1488(1-2):1-19. https://doi.org/10.1016/S1388-1981(00)00105-0
28. Burke JE, Dennis EA. Phospholipase A2 structure/function, mechanism, and signaling. J Lipid Res. 2009 Apr ;50(Suppl):S237. https://doi.org/10.1194/jlr.R800033-JLR200
29. Chwetzoff S, Tsunasawa S, Sakiyama F, Ménez A. Nigexine, a Phospholipase A2 from cobra venom with cytotoxic properties not related to esterase activity. J Biol Chem. 1989 Aug;264(22):13289- 97. https://doi.org/10.1016/S0021-9258(18)51627-6
30. Roberto PG, Kashima S, Marcussi S, Pereira JO, Astolfi-Filho S, Nomizo A, et al. Cloning and identification of a complete cDNA coding for a bactericidal and antitumoral acidic phospholipase A 2 from Bothrops jararacussu Venom. Protein J. 2004;23(4):273-85. https://doi.org/10.1023/B:JOPC.0000027852.92208.60
31. Kennedy AR. Chemopreventive agents: protease inhibitors. Epidemiol Data Suggest. Pharmacol. Ther. 1998;78:167-209. https://doi.org/10.1016/S0163-7258(98)00010-2
32. Young A, Byung MI, Lee MU, Yeong ', Kim S. Characterization and cytotoxicity of L-amino acid oxidase from the venom of king cobra (Ophiopkagus hannah). Int J Biochem Cell Biol. 1997;29:911-9. https://doi.org/10.1016/S1357-2725(97)00024-1
33. Zhang L, Wu WT. Isolation and characterization of ACTX-6: A cytotoxic L-amino acid oxidase from Agkistrodon acutus snake venom. Nat Prod Res. 2008 Apr 15;22(6):554-63. https://doi.org/10.1080/14786410701592679
34. Zhang L, Wei LJ. ACTX-8, a cytotoxic l-amino acid oxidase isolated from Agkistrodon acutus snake venom, induces apoptosis in Hela cervical cancer cells. Life Sci. 2007 Mar 6;80(13):1189-97. https://doi.org/10.1016/j.lfs.2006.12.024
35. Lm G, Sanchez EF, Sg S, Santos RG. Tumor cytotoxicity of Leucurolysin-B, a P-III snake venom metalloproteinase from Bothrops leucurus. J Venomous Anim Toxins Include Trop Dis. 2012;18(1):24-33. https://doi.org/10.1590/S1678-91992012000100004
36. Ârio M, Âsar C, Ãa C, Maria DA, Moura-Da-Silva AM, Pizzocaro KF, et al. Inhibition of melanoma cells tumorigenicity by the snake venom toxin jararhagin. Available from: www.elsevier.com/locate/ toxicon
37. Higuchi DA, Almeida MC, Barros CC, Sanchez EF, Pesquero PR, Lang EAS, et al. Leucurogin, a new recombinant disintegrin cloned from Bothrops leucurus (white-tailed-jararaca) with potent activity upon platelet aggregation and tumor growth. Toxicon. 2011 Jul;58(1):123-9. https://doi.org/10.1016/j.toxicon.2011.05.013
38. Swaim MW, Chiang2 HS, Huang2 TF. Characterisation of platelet aggregation induced by PC-3 human prostate adenocarcinoma cells and inhibited by venom peptides, trigramin and rhodostomin. Eur J Cancer. 1996 Apr;32A(4):715-21. https://doi.org/10.1016/0959-8049(95)00648-6
39. Chung KH, Kim SH, Han K yeon, Sohn YD, Chang SI, Baek KH, et al. Inhibitory effect of salmosin, a Korean snake venomderived disintegrin, on the integrin αv-mediated proliferation of SK-Mel-2 human melanoma cells. J Pharm Pharmacol. 2010 Feb 18;55(11):1577-82. https://doi.org/10.1211/0022357022160
40. Soszka T, Knudsen KA, Lucia Beviglia J, Rossi C, Poggi A, Niewiarowski S, et al. Inhibition of murine melanoma cell-matrix adhesion and experimental metastasis by albolabrin, an RGD-containing peptide isolated from the venom of Trimeresurus albolabris. Exp Cell Res. 1991 Sep;196(1):6-12. https://doi.org/10.1016/0014-4827(91)90449-5
41. Google Books. Handbook of Venoms and Toxins of Reptiles. [cited 2023 Jan 5]. Available from: https://books.google.co.in/ books?hl=en&lr=&id=x_vME799de4C&oi=fnd&pg=PA173&d-q=Doley+R,+Zhou+X,+Kini+RM.+Snake+venom+phospho-lipase+A2+enzymes.+In:+Handbook+of+venoms+and+tox-ins+of+reptiles.+CRC+Press/Taylor+and+Francis+Group%3B+20 09.+p.+173%E2%80%93205.&ots=PzK50HB-Qg&sig=lrutuXB¬ZH9Sll2tOfgFwD-i6as0&redir_esc=y#v=onepage&q&f=false
42. Dennis EA, Cao J, Hsu YH, Magrioti V, Kokotos G. Phospholipase A2 enzymes: Physical structure, biological function, disease implication, chemical inhibition, and therapeutic intervention. Chem Rev. 2011 Oct 12;111(10):6130-85. https://doi.org/10.1021/cr200085w
43. Gutiérrez J, Lomonte B. Phospholipase A2 myotoxins from Bothrops snake venoms. Toxicon. 1995 Nov 1;33(11):1405-24. https://doi.org/10.1016/0041-0101(95)00085-Z
44. Kini RM. Excitement ahead: structure, function and mechanism of snake venom phospholipase A2 enzymes. Toxicon. 2003 Dec 1;42(8):827-40. https://doi.org/10.1016/j.toxicon.2003.11.002
45. Berg OG, Gelb MH, Tsai MD, Jain MK. Interfacial enzymology: the secreted phospholipase A2-paradigm. Chem Rev. 2001 Sep;101(9):2613-53. https://doi.org/10.1021/cr990139w
46. Rowan EG. What does β-bungarotoxin do at the neuromuscular junction? Toxicon. 2001 Jan 1;39(1):107-18. https://doi.org/10.1016/S0041-0101(00)00159-8
47. Doley R, Kini RM. Protein complexes in snake venom. Cell Mol Life Sci. 2009 Jun 4;66(17):2851-71. https://doi.org/10.1007/s00018-009-0050-2
48. Kwong PD, McDonald NQ, Sigler PB, Hendrickson WA. Structure of beta 2-bungarotoxin: potassium channel binding by Kunitz modules and targeted phospholipase action. Structure. 1995;3(10):1109-19. https://doi.org/10.1016/S0969-2126(01)00246-5
49. Rodrigues R, Izidoro LF, de Oliveira Jr. R, Soares A, Rodrigues V, Sampaio S. Snake venom phospholipases A2: a new class of antitumor agents. Protein Pept Lett. 2009 Aug 1;16(8):894-8. https://doi.org/10.2174/092986609788923266
50. Benati RB, Costa TR, Cacemiro MDC, Sampaio SV, De Castro FA, Burin SM. Cytotoxic and pro-apoptotic action of MjTX-I, a phospholipase A2 isolated from Bothrops moojeni snake venom, towards leukemic cells. J Venom Anim Toxins Incl Trop Dis. 2018 Dec 20;24(1):40. https://doi.org/10.1186/s40409-018-0180-9
51. Marcussi S, Santos PRS, Menaldo DL, Silveira LB, Santos-Filho NA, Mazzi M V., et al. Evaluation of the genotoxicity of Crotalus durissus terrificus snake venom and its isolated toxins on human lymphocytes. Mutat Res Genet Toxicol Environ Mutagen. 2011 Sep 18;724(1-2):59-63. https://doi.org/10.1016/j.mrgentox.2011.06.004
52. Lomonte B, Angulo Y, Calderón L. An overview of lysine-49 phospholipase A2 myotoxins from crotalid snake venoms and their structural determinants of myotoxic action. Toxicon. 2003;42:885-901. https://doi.org/10.1016/j.toxicon.2003.11.008
53. Fujisawa D, Yamazaki Y, Lomonte B, Morita T. Catalytically inactive phospholipase A2 homologue binds to vascular endothelial growth factor receptor-2 via a C-terminal loop region. Biochem J. 2008 May 1;411(3):515-22. https://doi.org/10.1042/BJ20080078
54. Kessentini-Zouari R, Jebali J, Taboubi S, Srairi-Abid N, Morjen M, Kallech-Ziri O, et al. CC-PLA2-1 and CC-PLA2-2, two Cerastes cerastes venom-derived phospholipases A2, inhibit angiogenesis both in vitro and in vivo. Lab Investig. 2010;90:510-9. https://doi.org/10.1038/labinvest.2009.137
55. Bazaa A, Limam I, Kessentini-Zouari R, Kallech-Ziri O, El Battari A, Braguer D, et al. MVL-PLA2, a snake venom phospholipase A2, inhibits angiogenesis through an increase in microtubule dynamics and disorganization of focal adhesions. Available from: www. plosone.org
56. Bazaa A, Luis J, Srairi-Abid N, Kallech-Ziri O, Kessentini-Zouari R, Defilles C, et al. MVL-PLA2, a phospholipase A2 from Macrovipera lebetina transmediterranea venom, inhibits tumor cells adhesion and migration. Matrix Biol. 2009 May 1;28(4):188-93. https://doi.org/10.1016/j.matbio.2009.03.007
57. Corin RE, Viskatis LJ, Vidal JC, Etcheverry MA. Cytotoxicity of crotoxin on murine erythroleukemia cells in vitro. Investig New Drugs. 1993;11(1):11-15 https://doi.org/10.1007/BF00873905
58. Muller SP, Silva VAO, Silvestrini AVP, de Macedo LH, Caetano GF, Reis RM, et al. Crotoxin from Crotalus durissus terrificus venom: in vitro cytotoxic activity of a heterodimeric phospholipase A2 on human cancer-derived cell lines. Toxicon. 2018;156:13-22. https://doi.org/10.1016/j.toxicon.2018.10.306
59. Bezerra PHA, Ferreira IM, Franceschi BT, Bianchini F, Ambrósio L, Cintra ACO, et al. BthTX-I from Bothrops jararacussu induces apoptosis in human breast cancer cell lines and decreases cancer stem cell subpopulation. J Venom Anim Toxins Incl Trop Dis. 2019 Jul 29;25:e20190010. https://doi.org/10.1590/1678-9199-jvatitd-2019-0010
60. Khunsap S, Pakmanee N, Khow O, Chanhome L, Sitprija V, Suntravat M, et al. Purification of a phospholipase A 2 from Daboia russelii siamensis venom with anticancer effects. J Venom Res. 2011;2:42-51.
61. Jain D, Kumar S. Snake venom: a potent anticancer agent. Asian Pac J Cancer Prev. 2012 ;13(10):4855-60. https://doi.org/10.7314/APJCP.2012.13.10.4855
62. Fox JW, Serrano SMT. Timeline of key events in snake venom metalloproteinase research. J Proteomics. 2009 Mar 6;72(2):200-9. https://doi.org/10.1016/j.jprot.2009.01.015
63. Ferreira BA, Deconte SR, de Moura FBR, Tomiosso TC, Clissa PB, Andrade SP, et al. Inflammation, angiogenesis and fibrogenesis are differentially modulated by distinct domains of the snake venom metalloproteinase jararhagin. Int J Biol Macromol. 2018 ;119:1179- 87. https://doi.org/10.1016/j.ijbiomac.2018.08.051
64. Markland FS, Swenson S. Snake venom metalloproteinases. Toxicon. 2013 Feb ;62:3-18. https://doi.org/10.1016/j.toxicon.2012.09.004
65. Gutiérrez JM, Escalante T, Rucavado A, Herrera C. Hemorrhage caused by snake venom metalloproteinases: a journey of discovery and understanding. Toxins. 2016;8(4):93. https://doi.org/10.3390/toxins8040093
66. Sanchez EF, Flores-Ortiz RJ, Alvarenga VG, Eble JA. Direct fibrinolytic snake venom metalloproteinases affecting hemostasis: structural, biochemical features and therapeutic potential. Toxins. 2017 ;9(12):392. https://doi.org/10.3390/toxins9120392
67. Kini RM, Koh CY. Metalloproteases Affecting Blood Coagulation, Fibrinolysis and Platelet Aggregation from Snake Venoms: Definition and Nomenclature of Interaction Sites. Toxins. 2016;8(10):284. https://doi.org/10.3390/toxins8100284
68. Woodside DG, Vanderslice P. Inflammation and regulation by integrin cell adhesion antagonists. Transl Inflam. 2019 Jan 1;2019:43-68. https://doi.org/10.1016/B978-0-12-813832-8.00003-0
69. Olaoba OT, Karina dos Santos P, Selistre-de-Araujo HS, Ferreira de Souza DH. Snake venom metalloproteinases (SVMPs): a structure-function update. Toxicon X. 2020 Sep 1;7:100052. https://doi.org/10.1016/j.toxcx.2020.100052
70. Onyango OK. Isolation and characterization of snake venom proteins and peptides from members of Viperidae and Elapidae snake families from Kilifi County. 2018 [cited 2022 Aug 16]. Available from: http:// localhost/xmlui/handle/123456789/4764
71. Calderon LA, Sobrinho JC, Zaqueo KD, De Moura AA, Grabner AN, Mazzi M V, et al. Antitumoral activity of snake venom proteins: new trends in cancer therapy. 2014 [cited 2023 Sep 16]. Available from: http://dx.doi.org/10.1155/2014/203639 https://doi.org/10.1155/2014/203639
72. Maria AA, da Silva LGL, Correia CC, Ruiz GRG. Antiproliferative effect of the Jararhagin toxin on B16F10 murine melanoma. BMC Complement Altern Med. 2014 Nov 18;14(1):446. https://doi.org/10.1186/1472-6882-14-446
73. Ma R, Mahadevappa R, Kwok HF. Venom-based peptide therapy: insights into anti-cancer mechanism. Oncotarget. 2017; 2017:8. https://doi.org/10.18632/oncotarget.21740
74. Leonardi A, Sajevic T, Kova?i? L, Punger?ar J, Lang Balija M, Halassy B, et al. Hemorrhagin VaH4, a covalent heterodimeric P-III metalloproteinase from Vipera ammodytes ammodytes with a potential antitumour activity. Toxicon. 2014 Jan 1;77:141-55. https://doi.org/10.1016/j.toxicon.2013.11.009
75. Guimarães D de O, Lopes DS, Azevedo FVPV, Gimenes SNC, Silva MA, Achê DC, et al. In vitro antitumor and antiangiogenic effects of Bothropoidin, a metalloproteinase from Bothrops pauloensis snake venom. Int J Biol Macromol. 2017 Apr 1;97:770-7. https://doi.org/10.1016/j.ijbiomac.2017.01.064
76. Escalante T, Rucavado A, Fox JW, Gutiérrez JM. Key events in microvascular damage induced by snake venom hemorrhagic metalloproteinases. J Proteomics. 2011 ;74(9):1781-94. https://doi.org/10.1016/j.jprot.2011.03.026
77. Gutiérrez JM, Rucavado A, Escalante T, Díaz C. Hemorrhage induced by snake venom metalloproteinases: biochemical and biophysical mechanisms involved in microvessel damage. Toxicon. 2005 ;45(8):997-1011. https://doi.org/10.1016/j.toxicon.2005.02.029
78. Akhtar B, Muhammad F, Sharif A, Anwar MI. Mechanistic insights of snake venom disintegrins in cancer treatment. Eur J Pharmacol. 2021;899:174022. https://doi.org/10.1016/j.ejphar.2021.174022
79. Galán JA, Sánchez EE, Rodríguez-Acosta A, Soto JG, Bashir S, McLane MA, et al. Inhibition of lung tumor colonization and cell migration with the disintegrin crotatroxin 2 isolated from the venom of Crotalus atrox. Toxicon. 2008 Jun 1;51(7):1186-96. https://doi.org/10.1016/j.toxicon.2008.02.004
80. McLane MA, Joerger T, Mahmoud A. Disintegrins in health and disease. Front Biosci. 2008 May 1;13(17):6617-37 https://doi.org/10.2741/3177
81. Calvete JJ. The continuing saga of snake venom disintegrins. Toxicon. 2013 Feb 1;62:40-9. https://doi.org/10.1016/j.toxicon.2012.09.005
82. Hammouda MB, Montenegro MF, Sánchez-Del-Campo L, Zakraoui O, Aloui Z, Riahi-Chebbi I, et al. Lebein, A snake venom disintegrin, Induces apoptosis in human melanoma cells. Toxins (Basel). 2016 Jul 5;8:7. https://doi.org/10.3390/toxins8070206
83. Hong SY, Lee H, You WK, Chung KH, Kim DS, Song K. The snake venom disintegrin salmosin induces apoptosis by disassembly of focal adhesions in bovine capillary endothelial cells. Biochem Biophys Res Commun. 2003 Mar 14;302(3):502-8. https://doi.org/10.1016/S0006-291X(03)00213-4
84. Ghazaryan N, Movsisyan N, Macedo JC, Vaz S, Ayvazyan N, Pardo L, et al. The antitumor efficacy of monomeric disintegrin obtustatin in S-180 sarcoma mouse model. Invest New Drugs. 2019 Oct 1;37(5):1044-51. https://doi.org/10.1007/s10637-019-00734-2
85. Lino RLB, dos Santos PK, Pisani GFD, Altei WF, Cominetti MR, Selistre-de-Araújo HS. Alphavbeta3 integrin blocking inhibits apoptosis and induces autophagy in murine breast tumor cells. Biochim Biophys Acta. 2019 Dec 1;1866(12):118536. https://doi.org/10.1016/j.bbamcr.2019.118536
86. Danilucci TM, Santos PK, Pachane BC, Pisani GFD, Lino RLB, Casali BC, et al. Recombinant RGD-disintegrin DisBa-01 blocks integrin α v β 3 and impairs VEGF signaling in endothelial cells. Cell Commun Signal. 2019 Mar 20;17(1):27. https://doi.org/10.1186/s12964-019-0339-1
87. Chan YS, Cheung RCF, Xia L, Wong JH, Ng TB, Chan WY. Snake venom toxins: toxicity and medicinal applications. Appl Microbiol Biotechnol. . 2016 ;100(14):6165-81. https://doi.org/10.1007/s00253-016-7610-9
88. Costal-Oliveira F, Stransky S, Guerra-Duarte C, Naves de Souza DL, Vivas-Ruiz DE, Yarlequé A, et al. L-amino acid oxidase from Bothrops atrox snake venom triggers autophagy, apoptosis and necrosis in normal human keratinocytes. Sci Rep. 2019 ;9(1):781. https://doi.org/10.1038/s41598-018-37435-4
89. Ullah A, Masood R, Spencer PJ, Murakami MT, Arni RK. Crystallization and preliminary X-ray diffraction studies of an L-amino-acid oxidase from Lachesis muta venom. Acta Crystallogr F Struct Biol Commun. 2014 ;70(Pt 11):1556-9. https://doi.org/10.1107/S2053230X14017877
90. Kazianis S, Della Coletta L, Morizot DC, Johnston DA, Osterndorff EA, Nairn RS. Overexpression of a fish CDKN2 gene in a hereditary melanoma model. Carcinogenesis. 2000 ;21(4):599-605. https://doi.org/10.1093/carcin/21.4.599
91. Hanukoglu I. Proteopedia: Rossmann fold: a beta-alpha-beta fold at dinucleotide binding sites. Biochem Mol Biol Educ. 2015 May 1;43(3):206-9. https://doi.org/10.1002/bmb.20849
92. Pawelek PD, Cheah J, Coulombe R, Macheroux P, Ghisla S, Vrielink A. The structure of L-amino acid oxidase reveals the substrate trajectory into an enantiomerically conserved active site. EMBO J. 2000 Aug 15;19(16):4204-15. https://doi.org/10.1093/emboj/19.16.4204
93. Ullah A. Structure-function studies and mechanism of action of snake venom L-amino acid oxidases. Front Pharmacol. 2020 Feb 25;11:110. https://doi.org/10.3389/fphar.2020.00110
94. Lazo F, Vivas-Ruiz DE, Sandoval GA, Rodríguez EF, Kozlova EEG, Costal-Oliveira F, et al. Biochemical, biological and molecular characterization of an L-Amino acid oxidase (LAAO) purified from Bothrops pictus Peruvian snake venom. Toxicon. 2017 ;139:74-86. https://doi.org/10.1016/j.toxicon.2017.10.001
95. Takatsuka H, Sakurai Y, Yoshioka A, Kokubo T, Usami Y, Suzuki M, et al. Molecular characterization of l-amino acid oxidase from Agkistrodon halys blomhoffii with special reference to platelet aggregation. Biochim Biophys Acta. 2001 Jan 12;1544(1-2):267-77. https://doi.org/10.1016/S0167-4838(00)00229-6
96. Izidoro LFM, Ribeiro MC, Souza GRL, Sant'Ana CD, Hamaguchi A, Homsi-Brandeburgo MI, et al. Biochemical and functional characterization of an l-amino acid oxidase isolated from Bothrops pirajai snake venom. Bioorg Med Chem. 2006 Oct 15;14(20):7034- 43. https://doi.org/10.1016/j.bmc.2006.06.025
97. Toyama MH, Toyama DDO, Passero LFD, Laurenti MD, Corbett CE, Tomokane TY, et al. Isolation of a new L-amino acid oxidase from Crotalus durissus cascavella venom. Toxicon. 2006 Jan ;47(1):47- 57. https://doi.org/10.1016/j.toxicon.2005.09.008
98. Rey-Suárez P, Acosta C, Torres U, Saldarriaga-Córdoba M, Lomonte B, Núñez V. MipLAAO, a new L-amino acid oxidase from the redtail coral snake Micrurus mipartitus. PeerJ. 2018 ;2018(6):e4924. https://doi.org/10.7717/peerj.4924
99. Tempone AG, Spencer PJ, Lourenço CO, Rogero JR, Nascimento N, Andrade HF. Bothrops moojeni venom kills Leishmania spp. with hydrogen peroxide generated by its L-amino acid oxidase. Biochem Biophys Res Commun. 2001 ;280(3):620-4. https://doi.org/10.1006/bbrc.2000.4175
100. Costa TR, Menaldo DL, Zoccal KF, Burin SM, Aissa AF, Castro FAD, et al. CR-LAAO, an L-amino acid oxidase from Calloselasma rhodostoma venom, as a potential tool for developing novel immunotherapeutic strategies against cancer. Sci Rep. 2017 ;7(1):1- 12. https://doi.org/10.1038/srep42673
101. Sant'Ana CD, Menaldo DL, Costa TR, Godoy H, Muller VDM, Aquino VH, et al. RETRACTED: Antiviral and antiparasite properties of an l-amino acid oxidase from the Snake Bothrops jararaca: Cloning and identification of a complete cDNA sequence. Biochem Pharmacol. 2008 Jul 15;76(2):279-88. https://doi.org/10.1016/j.bcp.2008.05.003
102. NUUTINEN JT, Timonen S. Identification of nitrogen mineralization enzymes, l-amino acid oxidases, from the ectomycorrhizal fungi Hebeloma spp. and Laccaria bicolor. Mycol Res. 2008 Dec 1;112(12):1453-64. https://doi.org/10.1016/j.mycres.2008.06.023
103. Arima J, Sasaki C, Sakaguchi C, Mizuno H, Tamura T, Kashima A, et al. Structural characterization of l-glutamate oxidase from Streptomyces sp. X-119-6. FEBS J. 2009 ;276(14):3894-903. https://doi.org/10.1111/j.1742-4658.2009.07103.x
104. Schriek S, Kahmann U, Staiger D, Pistorius EK, Michel KP. Detection of an L-amino acid dehydrogenase activity in Synechocystis sp. PCC 6803. J Exp Bot. 2009 Mar ;60(3):1035. https://doi.org/10.1093/jxb/ern352
105. Nishizawa T, Aldrich CC, Sherman DH. Molecular analysis of the rebeccamycin L-amino acid oxidase from Lechevalieria aerocolonigenes ATCC 39243. J Bacteriol. 2005 Mar ;187(6):2084- 92. https://doi.org/10.1128/JB.187.6.2084-2092.2005
106. Matés JM, Sánchez-Jiménez FM. Role of reactive oxygen species in apoptosis: implications for cancer therapy. Int J Biochem Cell Biol. 2000 Feb 1;32(2):157-70. https://doi.org/10.1016/S1357-2725(99)00088-6
107. Singh M, Sharma H, Singh N. Hydrogen peroxide induces apoptosis in HeLa cells through mitochondrial pathway. Mitochondrion. 2007 Dec;7(6):367-73. https://doi.org/10.1016/j.mito.2007.07.003
108. Burin SM, Ayres LR, Neves RP, Ambrósio L, De Morais FR, Dias- Baruffi M, et al. L-amino acid oxidase isolated from bothrops pirajai induces apoptosis in BCR-ABL-positive cells and potentiates imatinib mesylate effect. Basic Clin Pharmacol Toxicol. 2013 Aug;113(2):103-12. https://doi.org/10.1111/bcpt.12073
109. Alves RM, Antonucci GA, Paiva HH, Cintra ACO, Franco JJ, Mendonça-Franqueiro EP, et al. Evidence of caspase-mediated apoptosis induced by l-amino acid oxidase isolated from Bothrops atrox snake venom. Comp Biochem Physiol. 2008;151(4):542-50. https://doi.org/10.1016/j.cbpa.2008.07.007
110. Abdelkafi-Koubaa Z, Elbini-Dhouib I, Souid S, Jebali J, Doghri R, Srairi-Abid N, et al. Pharmacological investigation of CC-LAAO, an L-Amino acid oxidase from Cerastes cerastes snake venom. Toxins. 2021 ;13(12):904. https://doi.org/10.3390/toxins13120904
111. Zhang L, Cui L. A cytotoxin isolated from Agkistrodon acutus snake venom induces apoptosis via Fas pathway in A549 cells. Toxicol in Vitro. 2007 Sep 1;21(6):1095-103. https://doi.org/10.1016/j.tiv.2007.04.008
112. Teixeira TL, Oliveira Silva VA, da Cunha DB, Polettini FL, Thomaz CD, Pianca AA, et al. Isolation, characterization and screening of the in vitro cytotoxic activity of a novel L-amino acid oxidase (LAAOcdt) from Crotalus durissus terrificus venom on human cancer cell lines. Toxicon. 2016 Sep 1;119:203-17. https://doi.org/10.1016/j.toxicon.2016.06.009
113. Momic T, Cohen G, Reich R, Arlinghaus FT, Eble JA, Marcinkiewicz C, et al. Vixapatin (VP12), a C-type lectin-protein from Vipera xantina palestinae venom: Characterization as a novel anti-angiogenic compound. Toxins (Basel). 2012 Oct;4(10):862-77. https://doi.org/10.3390/toxins4100862
114. De Castro Damasio D, Nolte S, Polak LP, Brandt AP, Bonan NB, Zischler L, et al. The lectin BJcuL induces apoptosis through TRAIL expression, caspase cascade activation and mitochondrial membrane permeability in a human colon adenocarcinoma cell line. Toxicon. 2014;90:299-307. https://doi.org/10.1016/j.toxicon.2014.08.062
115. Pathan J, Mondal S, Sarkar A, Chakrabarty D. Daboialectin, a C-type lectin from Russell's viper venom induces cytoskeletal damage and apoptosis in human lung cancer cells in vitro. Toxicon. 2017 Mar 1;127:11-21. https://doi.org/10.1016/j.toxicon.2016.12.013
116. Bonilla-Porras AR, Vargas LJ, Jimenez-Del-Rio M, Nuñez V, Velez- Pardo C. Purification of nasulysin-1: A new toxin from Porthidium nasutum snake venom that specifically induces apoptosis in leukemia cell model through caspase-3 and apoptosis-inducing factor activation. Toxicon. 2016 Sep 15;120:166-74. https://doi.org/10.1016/j.toxicon.2016.08.006
117. Boldrini-França J, Pinheiro-Junior EL, Peigneur S, Pucca MB, Cerni FA, Borges RJ, et al. Beyond hemostasis: a snake venom serine protease with potassium channel blocking and potential antitumor activities. Sci Rep. 2020 Dec 1;10(1):4476. https://doi.org/10.1038/s41598-020-61258-x
118. Bittenbinder MA, van Thiel J, Cardoso FC, Casewell NR, Gutiérrez JM, Kool J, et al. Tissue damaging toxins in snake venoms: mechanisms of action, pathophysiology and treatment strategies. Commun Biol. 2024;7(1):358. https://doi.org/10.1038/s42003-024-06019-6
119. Zhao Y sheng, Yang H ling, Liu C zheng. [Inhibitory effects of immunotargeting of Chinese cobra cytotoxin and iodine-131 against nasopharyngeal carcinoma cells in vitro]. Nan Fang Yi Ke Da Xue Xue Bao. 2008 Jul 1;28(7):1235-6.
120. Awwad S, Angkawinitwong U. Overview of antibody drug delivery. Pharmaceutics. 2018 Sep 1;10(3):83. https://doi.org/10.3390/pharmaceutics10030083
121. Chenthamara D, Subramaniam S, Ramakrishnan G, Krishnaswamy S, Essa MM, Lin FH, et al. Therapeutic efficacy of nanoparticles and routes of administration. Biomater Res. 2019;23:20. https://doi.org/10.1186/s40824-019-0166-x
122. Suralkar AR, Khedkar CS, Zanwar NR, Chandak CC, Gandhi SJ. Liposomes as a novel drug delivery system. GSC Biol Pharm Sci. 2022 Sep 30;20(3):336-43. https://doi.org/10.30574/gscbps.2022.20.3.0372
123. Vatankhah M, Dadashzadeh S, Mahboubi A, Haeri A, Jandaghi Alaee K, Mostafavi Naeini SB, et al. Preparation of multivesicular liposomes for the loco-regional delivery of Vancomycin hydrochloride using active loading method: drug release and antimicrobial properties. J Liposome Res. 2023; https://doi.org/10.1080/08982104.2023.2220805
124. Law LH, Huang J, Xiao P, Liu Y, Chen Z, Lai JHC, et al. Multiple CEST contrast imaging of nose-to-brain drug delivery using iohexol liposomes at 3T MRI. J Control Release. 2023 Feb 1;354:208-20. https://doi.org/10.1016/j.jconrel.2023.01.011
125. Nel J, Elkhoury K, Velot É, Bianchi A, Acherar S, Francius G, et al. Functionalized liposomes for targeted breast cancer drug delivery. Bioactive Mater. 2023;24:401-37. https://doi.org/10.1016/j.bioactmat.2022.12.027
126. Namakshenas P, Mojra A. Efficient drug delivery to hypoxic tumors using thermosensitive liposomes with encapsulated anti-cancer drug under high intensity pulsed ultrasound. Int J Mech Sci. 2023 Jan 1;237:107818. https://doi.org/10.1016/j.ijmecsci.2022.107818
127. Elsharkasy OM, Nordin JZ, Hagey DW, de Jong OG, Schiffelers RM, Andaloussi S EL, et al. Extracellular vesicles as drug delivery systems: Why and how? Adv Drug Deliv Rev. 2020 Jan 1;159:332- 43. https://doi.org/10.1016/j.addr.2020.04.004
128. Almeida H, Silva AC. Nanoparticles in ocular drug delivery systems. Pharmaceutics. 2023;15:1675. https://doi.org/10.3390/pharmaceutics15061675
129. Baldrick P. Nonclinical testing evaluation of liposomes as drug delivery systems. Int J Toxicol. 2023 Mar-Apr;42(2):122-34. https://doi.org/10.1177/10915818221148436
130. Chen CC, Liu L, Ma F, Wong CW, Guo XE, Chacko JV, et al. Elucidation of exosome migration across the blood-brain barrier model in vitro. Cell Mol Bioeng. 2016 Dec 1;9(4):509-29. https://doi.org/10.1007/s12195-016-0458-3
131. Jimidi Bhaskar S. A Recent advances in drug delivery to brain-a review. Asian J Pharm Res. 2024;14(1):668-87. https://doi.org/10.52711/2231-5691.2024.00013
132. Vader P, Mol EA, Pasterkamp G, Schiffelers RM. Extracellular vesicles for drug delivery . Adv Drug Deliv Rev. 2016;106:148-156. https://doi.org/10.1016/j.addr.2016.02.006
133. Alvarez-Erviti L, Seow Y, Yin H, Betts C, Lakhal S, Wood MJ. Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes. Nat Biotechnol. 2011;29(4):341-5. https://doi.org/10.1038/nbt.1807
134. Reddy SK, Ballal AR, Shailaja S, Seetharam RN, Raghu CH, Sankhe R, et al. Small extracellular vesicle-loaded bevacizumab reduces the frequency of intravitreal injection required for diabetic retinopathy. Theranostics. 2023;13(7):2241-55. https://doi.org/10.7150/thno.78426
135. Siddhardha B, Dyavaiah M, Kasinathan K. Model organisms to study biological activities and toxicity of nanoparticles. Springer Singapore; 2020. 1-466 p. https://doi.org/10.1007/978-981-15-1702-0
136. Jimenez-Canale J, Fernández-Quiroz D, Teran-Saavedra NG, Diaz-Galvez KR, Gallegos-Tabanico A, Burgara-Estrella AJ, et al. Cytotoxic activity of Crotalus molossus molossus snake venom-loaded in chitosan nanoparticles against T-47D breast carcinoma cells. Acta Biochim Pol. 2022;69(1):233-43.
137. Çelen Ç, Keçeciler C, Kar?? M, Göçmen B, Yesil-Celiktas O, Nalbantsoy A. Cytotoxicity of silica nanoparticles with transcaucasian nose-horned viper, Vipera ammodytes transcaucasiana, Venom on U87MG and SHSY5Y Neuronal Cancer Cells. Appl Biochem Biotechnol. 2018 Oct 1;186(2):350-7. https://doi.org/10.1007/s12010-018-2742-2
138. Badr G, Al-Sadoon MK, Rabah DM, Sayed D. Snake (Walterinnesia aegyptia) venom-loaded silica nanoparticles induce apoptosis and growth arrest in human prostate cancer cells. Apoptosis. 2013 Mar;18(3):300-14. https://doi.org/10.1007/s10495-012-0787-1
139. Chen D, Liu X, Lu X, Tian J. Nanoparticle drug delivery systems for synergistic delivery of tumor therapy. Frontiers Media S.A.; 2023. https://doi.org/10.3389/fphar.2023.1111991
140. Srinivas T, Parvathi D, Devi UA. Advancements in nanoparticle applications for targeted drug delivery: benefits and implications. Int J Biol Res. 2024 Jul 26;11(2):50-6. https://doi.org/10.14419/gqvh1v53
141. Ani AC, Emencheta SC, Orah KJ, Upaganlawar AB, Prajapati BG, Oranu CK, et al. Targeted nanotechnology-based formulations. Alzheimer's disease and advanced drug delivery strategies. Elsevier; 2023. p. 347-59. https://doi.org/10.1016/B978-0-443-13205-6.00007-8
142. Whitford W, Guterstam P. Exosome manufacturing status. Future Med Chem. 2019 ;11(10):1225-36. https://doi.org/10.4155/fmc-2018-0417
143. Kishore BK, Park F, Ecelbarger CM, Lv LL, Liu BC, Tang TT, et al. Extracellular vesicles: opportunities and challenges for the treatment of renal diseases. Front Physiol. 2019 ;1:226.
144. Lee JC, Ray RM, Scott TA. Prospects and challenges of tissue-derived extracellular vesicles. Molecular Therapy. Cell Press; 2024. https://doi.org/10.1016/j.ymthe.2024.06.025
145. Lee J, Kim J, Jeong M, Lee H, Goh U, Kim H, et al. Liposome-based engineering of cells to package hydrophobic compounds in membrane vesicles for tumor penetration. Nano Lett. 2015;15(5):2938-44. https://doi.org/10.1021/nl5047494
146. Tian Y, Li S, Song J, Ji T, Zhu M, Anderson GJ, et al. A doxorubicin delivery platform using engineered natural membrane vesicle exosomes for targeted tumor therapy. Biomaterials. 2014 ;35(7):2383-90. https://doi.org/10.1016/j.biomaterials.2013.11.083
147. Kim MS, Haney MJ, Zhao Y, Mahajan V, Deygen I, Klyachko NL, et al. Development of exosome-encapsulated paclitaxel to overcome MDR in cancer cells. Nanomedicine. 2016 ;12(3):655-64 https://doi.org/10.1016/j.nano.2015.10.012
148. Haney MJ, Klyachko NL, Zhao Y, Gupta R, Plotnikova EG, He Z, et al. Exosomes as drug delivery vehicles for Parkinson's disease therapy. J Control Release. 2015 ;207:18-30. https://doi.org/10.1016/j.jconrel.2015.03.033
149. Li Z, Zhou X, Wei M, Gao X, Zhao L, Shi R, et al. In vitro and in vivo RNA Inhibition by CD9-HuR Functionalized Exosomes Encapsulated with miRNA or CRISPR/dCas9. Nano Lett. 2019 ;19(1):19-28. https://doi.org/10.1021/acs.nanolett.8b02689
150. Feng T, Huang X, Ni R, Suen WLL, Chau Y. Nanoparticles for drug delivery targeting neurodegeneration in brain and eye. Nanomater Drug Deliv Ther. 2019; 2019:149-83. https://doi.org/10.1016/B978-0-12-816505-8.00006-0
151. Yang P, Ren J, Yang L. Nanoparticles in the new era of cardiovascular therapeutics: challenges and opportunities. Int J Mol Sci. 2023; 2023:24. https://doi.org/10.3390/ijms24065205
152. Alkufi H, Salman A, Taher S. Principles and Advantages of New Drug Delivery Technologie. J Complem Med Res. 2023;14(3):6. https://doi.org/10.5455/jcmr.2023.14.03.02
153. Hami Z. A Brief review on advantages of nano-based drug delivery systems. Ann Milit Health Sci Res. 2021 Mar 6;19(1):541-69. https://doi.org/10.5812/amh.112274
154. Wang L, Song Y, Wang H, Zhang X, Wang M, He J, et al. Advances of artificial intelligence in anti-cancer drug design: a review of the past decade. Pharmaceuticals. 2023;16:253. https://doi.org/10.3390/ph16020253
155. Tan P, Chen X, Zhang H, Wei Q, Luo K. Artificial intelligence aids in development of nanomedicines for cancer management. Semin Cancer Biol. 2023 Feb 1;89:61-75. https://doi.org/10.1016/j.semcancer.2023.01.005
156. Moebius K, Eichler J. HIV-derived peptide mimics. Drug Discov Today Technol. 2009 Jan 1;6(1-4):e19-25. https://doi.org/10.1016/j.ddtec.2009.09.001
157. Díaz-Gómez JL, Martín-Estal I, Rivera-Aboytes E, Gaxiola-Muñíz RA, Puente-Garza CA, García-Lara S, et al. Biomedical applications of synthetic peptides derived from venom of animal origin: a systematic review. Biomed Pharmacother. 2024;170:116015. https://doi.org/10.1016/j.biopha.2023.116015

Article Metrics

Similar Articles

Related Search

By author names

Ramesh D [PubMed] [Google Scholar ]
Bakkannavar S M [PubMed] [Google Scholar ]
Kumar G [PubMed] [Google Scholar ]
V R B [PubMed] [Google Scholar ]